Stocks
Eli Lilly and Company (LLY) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 413.4% | 299.9% | 375.1% | 289.5% | 126.0% | 128.3% | |||
| Changes by years, y/y, % | +246pp | -113pp | +75pp | -86pp | -163pp | -5.5% | |||
Eli Lilly and Company. R&D/CAPEX, %
Eli Lilly and Company. R&D/CAPEX, changes, pp
Eli Lilly and Company (LLY) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| R&D/CAPEX, % | 60.2% | 155.2% | 255.8% | 193.3% | 65.6% | 128.3% | ||
| Changes by years, y/y, % | -230pp | -204pp | +36pp | -89pp | +5pp | |||
| Changes by quarters, q/q, % | -222pp | +95pp | +101pp | -63pp | -128pp | |||
